Chemotherapy vs. "TKI + immunotherapy" in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene

Ann Hematol. 2024 Aug;103(8):3257-3259. doi: 10.1007/s00277-024-05816-7. Epub 2024 May 29.

Authors

Yan Li¹, Qin Zhang², Haigang Shao³

Affiliations

¹ Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
² Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
³ Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China. xya3shg@163.com.

PMID: 38809455
DOI: 10.1007/s00277-024-05816-7

No abstract available

Publication types

Letter
Case Reports
Comparative Study

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Humans
Immunotherapy
Intracellular Signaling Peptides and Proteins
Male
Middle Aged
Oncogene Proteins, Fusion* / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Protein Kinase Inhibitors* / therapeutic use

Substances

Intracellular Signaling Peptides and Proteins
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
RCSD1 protein, human